You are here

Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Healthy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-80 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Men aged 18 to 45 years inclusive on study day 1.

- Elderly men and women aged 65 to 80 years inclusive on study day 1.

- Women must be postmenopausal for > or = 1 year (with estradiol
40 mIU/mL).

- Healthy as determined by the investigator on the basis of medical history, physical
examination, vital signs, clinical laboratory test results, and 12-leave
electrocardiogram.

- Elderly subjects may have stable, nonclinically significant abnormalities on physical
examination, and laboratory evaluation.

- Non-smoker.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Men aged 18 to 45 years inclusive on study day 1.

- Elderly men and women aged 65 to 80 years inclusive on study day 1.

- Women must be postmenopausal for > or = 1 year (with estradiol
40 mIU/mL).

- Healthy as determined by the investigator on the basis of medical history, physical
examination, vital signs, clinical laboratory test results, and 12-leave
electrocardiogram.

- Elderly subjects may have stable, nonclinically significant abnormalities on physical
examination, and laboratory evaluation.

- Non-smoker.

NCT00563810
Pfizer
Completed
Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029
An Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029 Administered Intravenously as a 30-Minute Infusion to Healthy Subjects
This is a multiple dose study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of an investigational new drug.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Health Services Research
Healthy
Drug: MYO-029
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
72
April 2006
Not Provided

Inclusion Criteria:

  • Men aged 18 to 45 years inclusive on study day 1.
  • Elderly men and women aged 65 to 80 years inclusive on study day 1.
  • Women must be postmenopausal for > or = 1 year (with estradiol < 25 pg/mL and an FSH > 40 mIU/mL).
  • Healthy as determined by the investigator on the basis of medical history, physical examination, vital signs, clinical laboratory test results, and 12-leave electrocardiogram.
  • Elderly subjects may have stable, nonclinically significant abnormalities on physical examination, and laboratory evaluation.
  • Non-smoker.
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00563810
3147K1-103
Not Provided
Not Provided
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
November 2007

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now